In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative to an existing protein biologic drug called Neupogen made by Amgen. In reviewing the FDA’s […]
Nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs) present in the human body have been suggested as a new delivery platform for a range of therapeutics for cancer chemotherapy, heart disease, and infectious diseases. FDA approved drugs such as immunotherapeutic proteins, single-stranded DNA, small molecule drugs such as doxorubicin can be […]
Creative PEGWorks has collected hundreds of papers published in peer-reviewed journals citing the use of PEG derivatives for PEGylation of proteins, enzymes, antibodies, peptides, biologic, nucleic acids, nanoparticles, chips, surfaces, dendrimers, hydrogels, liposomes and micelles. These paper describe detailed procedures and chemistry reaction conditions as well as experiment characterization data for the use of PEGylation […]
A research group from the Republic of Korea developed poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) with high tumor targetability. Doxorubicin (DOX) was chosen as the model anticancer drug and was effectively encapsulated into the mineralized nanoparticles. “The most effective antitumor efficacy was observed for DOX-loaded PEG-HANPs. Overall, these results suggest that PEG-HANPs could be a […]
Creative PEGWorks developed a series of amphiphilic, surfactant-like PEG derivatives and they are now available for purchase at www.creativepegworks.com. PEG surfactants and pegylated lipids can be used for drug delivery and formulation, to enhance drug solubility, improve bioavailability and pharmacokinetics, enable targeting cell receptors, and amplify imaging signals. Successful examples include pegylated liposome (Doxil), and […]
Researchers from the Massachusetts General Hospital and Harvard Medical School developed novel “PEG-like Nanoprobes’’ with controllable pharmacokinetics and tunable fluorescence. The “PEG-like Nanoprobes’’ nanoparticles feature a unique design where a single PEG polymer surrounds a short fluorochrome and radiometal bearing peptide, and endows the resulting nanoprobe with pharmacokinetic control (based on molecular weight of the […]
Researchers from University of Washington and the Howard Hughes Medical Institute use an innovative computational design approach coupled with in-vitro-targeted evolution to produce a potent polypeptide inhibitor that triggers apoptosis of virus-infected cancer cells, suppresses tumor growth and extends survival in a xenograft model of EBV-positive human lymphoma. This represents an effort to generate biologically […]
